Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Estianeptine - Tonix Pharmaceuticals Holding Corp

Next Previous
Drug Profile

Estianeptine - Tonix Pharmaceuticals Holding Corp

Alternative Names: Single (S)-isomer tianeptine - Tonix Pharmaceuticals; TNX-4300

Latest Information Update: 02 Aug 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tonix Pharmaceuticals Holding Corp
  • Class Antidementias; Antiparkinsonians; Mood stabilisers; Small molecules; Thiazepines; Tricyclic antidepressants
  • Mechanism of Action Peroxisome proliferator-activated receptor delta agonists; PPAR gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alzheimer's disease; Bipolar disorders; Major depressive disorder; Parkinson's disease

Most Recent Events

  • 26 Jul 2023 Tonix files patents claiming single (S)-isomer estianeptine and crystalline salt forms of estianeptine that appear well suited to formulation
  • 23 May 2023 Tonix Pharmaceuticals announces intention to submit IND application (Tonix Pharmaceuticals pipeline, May 2023)
  • 23 May 2023 Preclinical trials in Alzheimer's disease in USA (PO) before May 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top